FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 358 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR 24-Year-Old Diagnosed With Breast Cancer After Doctors Said Her Chest Was... January 27, 2020 What Happens If More People Get Screened for Cancer? January 26, 2024 Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in... June 8, 2026 Neoadjuvant Nivolumab Plus Chemotherapy Results in Significantly Longer Event-Free Survival in... May 3, 2022 Load more HOT NEWS Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients... Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer Help seeking: Why isn’t it as simple as it might sound? FDA Approves Sacituzumab Govitecan-hziy for HR-positive Advanced Breast Cancer
